Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.

@article{Joly2016RictormTORC2DP,
  title={Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.},
  author={Meghan Morrison Joly and Donna J. Hicks and Bayley Jones and Violeta Sanchez and M Valeria Estrada and Christian D. Young and Michelle M. Williams and Brent N. Rexer and Dos D. Sarbassov and William J. Muller and Dana M. Brantley-Sieders and Rebecca S. Cook},
  journal={Cancer research},
  year={2016},
  volume={76 16},
  pages={4752-64}
}
HER2 overexpression drives Akt signaling and cell survival and HER2-enriched breast tumors have a poor outcome when Akt is upregulated. Akt is activated by phosphorylation at T308 via PI3K and S473 via mTORC2. The importance of PI3K-activated Akt signaling is well documented in HER2-amplified breast cancer models, but the significance of mTORC2-activated Akt signaling in this setting remains uncertain. We report here that the mTORC2 obligate cofactor Rictor is enriched in HER2-amplified samples… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Similar Papers

Loading similar papers…